Novo Nordisk A/S Investors: Please contact the Portnoy Law Firm to recover your losses; March 25, 2025 Deadline to file Lead Plaintiff Motion

Core Viewpoint - A class action lawsuit has been initiated against Novo Nordisk A/S, alleging that the company made false or misleading statements regarding its CagriSema obesity treatment during the class period from November 2, 2022, to December 19, 2024, leading to significant investor losses [1][3]. Summary by Sections Class Action Details - Investors who purchased Novo Nordisk securities during the specified class period can file a lead plaintiff motion by March 25, 2025 [1]. - The Portnoy Law Firm is offering complimentary case evaluations to affected investors [2]. Allegations Against Novo Nordisk - The lawsuit claims that Novo Nordisk misrepresented the reliability of projected success for the Phase 3 CagriSema obesity study, "REDEFINE-1," and did not adequately discuss dosage tolerability [5]. - The company’s claims that CagriSema would achieve at least 25% weight loss in the REDEFINE-1 study were deemed unrealistic [5]. - The flexible protocol of the study limited its ability to provide meaningful weight loss data, suggesting potential issues with dosage tolerability or a rushed patient selection process [5]. Impact on Stock Price - Following the release of results from the REDEFINE-1 trial on December 20, 2024, Novo Nordisk's stock price experienced a nearly 18% drop, indicating a significant market reaction to the disclosed information [3].